Highlighting a quarter in which all of its major products provided sequential sales growth with most also growing year-over-year, AbbVie Inc. reported on 30 October that Botox (onabotulinumtoxinA) for both therapeutic and cosmetic indications achieved the strong rebound the firm predicted during its second quarter earnings call in July.
In general, analysts hailed AbbVie’s Q3 2020 performance in which many products topped consensus revenue estimates. In a same-day note,...








